Seropositivity for pathogens associated with chronic infections is a risk factor for all-cause mortality in the elderly: findings from the Memory and Morbidity in Augsburg Elderly (MEMO) Study

Marius Zeeb · Tobias Kerrinnes · Luka Cicin-Sain · Carlos A. Guzman · Wolfram Puppe · Thomas F. Schulz · Annette Peters · Klaus Berger · Stefanie Castell · André Karch

Received: 17 April 2020 /Accepted: 11 June 2020 /Published online: 9 July 2020
© The Author(s) 2020

Abstract Immunostimulation by chronic infection has been linked to an increased risk for different non-communicable diseases, which in turn are leading causes of death in high- and middle-income countries. Thus, we investigated if a positive serostatus for pathogens responsible for common chronic infections is individually or synergistically related to reduced overall survival in community dwelling elderly. We used data of 365 individuals from the German MEMO (Memory and Morbidity in Augsburg Elderly) cohort study with a median age of 73 years at baseline and a median follow-up of 14 years. We examined the effect of a positive
seropositivity to pathogens responsible for chronic infections like CMV might be linked to all-cause mortality (Simanek et al. 2011). However, the current literature lacks long-term cohort studies, which examine not only the effect of one but also of a combination of several chronic infections on all-cause mortality in the elderly. The aim of our study was to investigate the effect of the serostatus of seven pathogens associated with chronic infections (CMV, HHV-6, EBV, HSV-1/2, H. pylori, T. gondii, and B. burgdorferi s.l.) on all-cause mortality using data of 365 older individuals with a median follow-up of 14 years from the Memory and Morbidity in Augsburg Elderly (MEMO) Study. The seven pathogens were selected because all of them are closely associated with chronic infections and are sufficiently prevalent in the source population to be assessed in the context of this study.

Methods

Study population

We used data from the MEMO study (n = 385), a German cohort of individuals between 65 and 83 years of age at baseline (Braune and Berger 2005). MEMO is a
subcohort of the MONICA S2 cohort (WHO 1988), focusing specifically on diseases of the elderly. Study participants were phenotyped in Augsburg, Germany in 1997/1998 (start of follow-up) including collection of blood. For this analysis, we excluded 20 individuals for whom no serum sample was available. MEMO was approved by the ethics committee of the University of Münster, Germany; all individuals provided written informed consent.

Definition of exposure

To measure the IgG-antibody titers against pre-defined pathogens responsible for chronic infections, we used the “Helicobacter pylori IgG ELISA” (IBL International, (REF) RE56381) (cut-off index for a positive result of > 1.2), the “Toxoplasma gondii IgG ELISA” (IBL International, (REF) RE58371) (cut-off index for a positive result of > 1.2), and the “Borrelia burgdorferi s.l. Europe plus TpN17 LINE IgG Line Immunoblot” (Virotech diagnostics, (REF) WE225G32). We also measured CMV IgG-antibody titers (cut-off for positive >= 6 AU/ml) with Architect-CMV-IgG (Abbott-Diagnostics, (REF) 6C1530) and EBV IgG-antibody titers (signal to cut-off ratio for positive >= 1) with Architect-EBV-VCA-IgG (Abbott-Diagnostics, (REF) 3P6525), HHV-6 IgG-antibody titers (signal to cut-off ratio for positive > 1.1 and for seroborderline >= 0.9 to < = 1.1) with Anti-HHV-6-IgG ELISA-VIDITEST (VIDIA, (REF) ODZ-235), and HSV-1/2 IgG-antibody titers (cut-off for positive > 1.1) with LIASION-HSV-1/2 IgG (DiaSorin S.p.A., (REF) 310,800), according to the manufacturer’s instructions. For the primary analysis, we dichotomized all antibody titers into seropositive or seronegative, according to the manufacturers’ manual. However, B. burgdorferi s.l. and HHV-6 were, according to the manual, trichotomized into seropositive, seronegative, and seroborderline (when the measurement was between two threshold values). We considered individuals seroborderline for B. burgdorferi s.l. or HHV-6 as seronegative in the primary analysis. Based on the dichotomized serostatus, we calculated an infection sum score to examine the cumulative effect of seropositivity for each individual. This score consisted of values from two to seven; no individual was seropositive for zero or only one infectious agent. We performed sensitivity analyses in which we considered the individuals seroborderline for B. burgdorferi s.l. and HHV-6 as seropositive. Moreover, we constructed separate cumulative scores for viruses and bacteria/protozoa using the same approach. In an additional sensitivity analysis, we divided CMV, H. pylori-, and B. burgdorferi s.l. antibody titers into quartiles for a better comparison with the previous literature.

Definition of outcome

We defined all-cause mortality as derived by official cause of death certificates from local health departments as the outcome of interest. Four mortality follow-ups were performed since the initiation of MEMO (latest December 2015). Individuals, who were not reported to be dead, were censored at the time of the last mortality assessment, if they were not lost to follow up.

Definition of covariables

Using the disjointive cause criterion (VanderWeele and Shpitser 2011) for confounder identification, we included age (in years), sex, socioeconomic status (SES) (Donnelly et al. 2018), history of stroke (Chamorro et al. 2007), any kind of cancer (Rolston 2017), myocardial infarction (Truffà et al. 2012), diabetes mellitus type 1 or 2 (Casqueiro et al. 2012), smoking status (Bagaitkar et al. 2008), BMI (kg/m²; with BMI > 30 defined as obese according to WHO definition (Dobner and Kaser 2018; WHO 2019)), and hypertension as potential confounders (Gu et al. 2017). All potential confounders were assessed as self-reported variables at baseline only, using a standardized interview. Due to the limited information available in MEMO, we used the number of education years (including apprenticeships) as a surrogate for SES. We considered individuals who had not reported a comorbidity as not having the respective comorbidity in the primary analysis. Given the limited sample size of the study, we adapted the approach of Diederichs et al. to the field of time to event analyses to calculate a weighted comorbidity score (based on cox proportional hazard regression) in order to keep the model parsimonious (Diederichs et al. 2012).

Statistical methods

We calculated the accelerated failure time (AFT) and its 95% confidence interval (CI) in a parametric survival model based on a Weibull distribution assumption to describe the effect of serostatus on all-cause mortality.
We assessed the constant hazard assumption graphically. We used parametric survival models because constant hazards of death could be assumed, whereas the proportional hazards assumption crucial for semiparametric survival models was not fulfilled in many of the models to be performed. We first calculated AFT in univariable analyses including serostatus only, as well as in multivariable analyses adjusted for age (continuous), sex (binary), number of education years (continuous), and the comorbidity score (continuous, ranging from 0 to 2.5). In a second step, we used the cumulative infection score (both continuously and categorically, to assess the functional form of a possible effect) instead of single infections in the univariable and the adjusted multivariable analysis. In the sensitivity analysis based on separate scores for viruses and bacteria/protozoa as well as in the sensitivity analyses based on quartiles of the CMV-, *H. pylori*, and *B. burgdorferi s.l.* IgG antibody titer distribution, we used the same analysis approach as for the cumulative infection score. AFTs (where the null hypothesis of no effect is represented by 0, and effects are represented as a relative decrease or increase in survival time in percent) were also transformed into hazard ratios (HR, where no effects correspond to a HR of 1) for better comparison with the literature. We conducted all analyses using the package “survival” (Therneau 2015) in R version 3.6.1.

### Results

The 365 study participants had a median age of 73 years (interquartile range 69–76) at baseline; 46% were women (Table 1). Of all participants 250 died during follow-up (68%); median survival time until the last vital status follow-up was 14 years. Seropositivity in this study varied between 13% for *B. burgdorferi s.l.* and 99% for EBV. Females were more likely to be seropositive for CMV and HHV-6, but less likely to be seropositive for *H. pylori* and *B. burgdorferi s.l.* (Supplementary Table 4). Moreover, being seropositive for CMV and HHV-6 was associated with a body mass index of 30 or above (Supplementary Table 4). Among the seven chronic infections investigated, reduced survival time was observed for those seropositive for *H. pylori* (AFT −15.92, 95% CI −29.96; −1.88), CMV (AFT −22.81, 95% CI −36.42; −9.22), and *B. burgdorferi s.l.* (AFT −25.25, 95% CI −43.40; −7.10) after adjusting for potential confounders (Table 2). We did not find evidence for an effect of seropositivity for EBV, HSV-1/2, *T. gondii*, or HHV-6 on overall survival (Fig. 1). However, confidence intervals were wide for EBV and HSV-1/2 given the low number of seronegative individuals. The cumulative infection score showed a clear association with reduced survival in the multivariable analysis (AFT −12.42, 95% CI −18.55; −6.30, per additional score point; Fig. 2 and Table 3). This was consistent across all age groups (Supplementary Table 9). Results for separate scores for viruses and bacteria/protozoa were in line with the main analyses. When we considered seroborderline results as seropositive, seropositivity for *B. burgdorferi s.l.* no longer as strongly associated with reduced survival as in the primary analysis (AFT −9.66, 95% CI −25.21; 5.88) (Supplementary Table 1). Increasing CMV antibody titers (when divided in quartiles) were associated with reduced survival in the multivariable analysis (AFT −8.53, 95% CI −14.14; −2.93, per quartile rising, Fig. 3 and Table 4), while there was no difference between the

### Table 1 Baseline characteristics of study participants (n = 365)

| Demographic characteristics | Study population |
|----------------------------|-----------------|
| Female, n (%)              | 168 (46%)       |
| Age, median, min to max    | 73, 65–83       |
| Number of education years, median, min to max | 10, 8–17 |
| Follow-up years, median, 1st and 3rd quartile | 14, 8–18 |
| Comorbidities and risk factors          |                |
| Body mass index > 30, n (%)       | 88 (24%)        |
| History of stroke, n (%)          | 24 (7%)         |
| History of any cancer, n (%)      | 13 (4%)         |
| History of myocardial infarction, n (%) | 33 (9%)       |
| Diabetes mellitus, n (%)          | 39 (11%)        |
| Smoking, n (%)                  | 186 (51%)       |
| Hypertension, n (%)              | 173 (47%)       |
| Serostatus for selected pathogens |                |
| *B. burgdorferi s.l.*, n (%)     | 46 (13%)        |
| Seroborderline for *B. burgdorferi s.l.*, n (%) | 30 (8%) |
| CMV, n (%)                     | 214 (59%)       |
| HHV-6, n (%)                   | 216 (59%)       |
| Seroborderline for HHV-6, n (%)  | 23 (6%)         |
| *H. pylori*, n (%)              | 230 (63%)       |
| *T. gondii*, n (%)              | 297 (81%)       |
| HSV-1/2, n (%)                  | 357 (98%)       |
| EBV, n (%)                      | 362 (99%)       |
| Cumulative infection score, median, min to max | 5, 2–7 |

*Table 1* Baseline characteristics of study participants (n = 365)
Table 2  Association between seropositivity for selected chronic infections and all-cause mortality ($n = 365$)

| Infectious agent | Deaths | Follow-up years | Univariable analysis | Multivariable analysis* |
|------------------|--------|----------------|----------------------|-------------------------|
|                  |        |                | AFT in % (95%-CI)    | HR (95%-CI)             | AFT in % (95%-CI)    | HR (95%-CI)             |
| *H. pylori*      |        |                |                      |                         |                        |                        |
| Seropositive ($n = 230$) | 170    | 2777           | -22.32 (-37.45; -7.19) | 1.48 (1.14; 1.94)       | -15.92 (-29.96; -1.88) | 1.36 (1.04; 1.79)       |
| Seronegative ($n = 135$) | 80     | 1830           | 0                    | 1                       | 0                       | 1                       |
| *T. gondii*      |        |                |                      |                         |                        |                        |
| Seropositive ($n = 297$) | 200    | 3730           | 3.44 (-14.24; 21.12)  | 0.94 (0.69; 1.28)       | -1.34 (-17.44; 14.76)  | 1.03 (0.75; 1.40)       |
| Seronegative ($n = 68$) | 50     | 877            | 0                    | 1                       | 0                       | 1                       |
| *B. burgdorferi s.l.*** |    |                |                      |                         |                        |                        |
| Seropositive ($n = 46$) | 37     | 522            | -21.52 (-41.41; -1.63) | 1.46 (1.03; 2.07)       | -25.25 (-43.4; -7.10)  | 1.64 (1.15; 2.35)       |
| Seronegative ($n = 319$) | 213    | 4085           | 0                    | 1                       | 0                       | 1                       |
| *CMV*            |        |                |                      |                         |                        |                        |
| Seropositive ($n = 214$) | 161    | 2531           | -26.37 (-41.11; -11.63) | 1.60 (1.23; 2.07)       | -22.81 (-36.41; -9.22) | 1.56 (1.20; 2.03)       |
| Seronegative ($n = 151$) | 89     | 2076           | 0                    | 1                       | 0                       | 1                       |
| *HHV-6***        |        |                |                      |                         |                        |                        |
| Seropositive ($n = 216$) | 151    | 2714           | -4.25 (-18.71; 10.21) | 1.08 (0.84; 1.39)       | -5.22 (-18.38; 7.94)   | 1.11 (0.86; 1.43)       |
| Seronegative ($n = 149$) | 99     | 1893           | 0                    | 1                       | 0                       | 1                       |
| *HSV-1/2*        |        |                |                      |                         |                        |                        |
| Seropositive ($n = 357$) | 245    | 4514           | -1.79 (-52.32; 48.74) | 1.03 (0.43; 2.50)       | -28.93 (-75.02; 17.16) | 1.75 (0.72; 4.29)       |
| Seronegative ($n = 8$) | 5      | 93             | 0                    | 1                       | 0                       | 1                       |
| *EBV*            |        |                |                      |                         |                        |                        |
| Seropositive ($n = 362$) | 249    | 4558           | -61.02 (-173.12; 51.09) | 2.92 (0.41; 20.78)      | -34.96 (-137.38; 67.45) | 1.97 (0.27; 14.30)       |
| Seronegative ($n = 3$) | 1      | 49             | 0                    | 1                       | 0                       | 1                       |

*aadjusted for age, sex, education years and a comorbidity index

**seroborderline as seronegative
upper three antibody titer quartiles for *B. burgdorferi s.l.* and *H. pylori*. All additional sensitivity analyses led to qualitatively unchanged results when compared to the primary analysis (Supplementary Table 1–9).
**Discussion**

Our results indicate that community dwelling individuals older than 65 years seropositive for *H. pylori*, *B. burgdorferi s.l.*, or CMV have a reduced overall survival time compared with seronegative individuals after adjustment for potential confounders.

Within our study, CMV seropositivity had the largest individual effect on all-cause mortality (HR: 1.56, 95% CI 1.20; 2.03). This confirms results of three previous cohort studies, which all reported decreased survival time in individuals seropositive for CMV. A study from the UK focused as well on elderly individuals (mean age 74), and reported an HR of 1.35 (95% CI 1.04; 1.75) (Savva et al. 2013) which is in line with the effect estimate in our study. An analysis based on NHANES III (National Health and Nutrition Examination Survey III 1988–1994) data from the USA reported a smaller effect size of CMV seropositivity on all-cause mortality than our study with an HR of 1.19 (95% CI 1.01; 1.41). The mean age in NHANES was, however, considerably lower than in our study with 51 years for seropositive and 41 years for seronegative individuals at baseline (Simanek et al. 2011). Assuming that most individuals were infected approximately at the same age in the NHANES III and in our study, this may imply that a longer exposure time to the chronic infectious agent results in a cumulative adverse effects. Alternatively, the difference in effect size between our population and the one in the younger NHANES III cohort may imply that adverse CMV effects are more pronounced in older people. CMV may prompt a stronger inflammatory response, which, superposed with the natural age-related increase in inflammation in the organism, may increase an individual’s vulnerability for NCDs and its risk of dying earlier (De Martinis et al. 2005). This is supported by our recent experimental study in an animal model of CMV infection that has shown that latent CMV infection of fat tissue induces inflammatory responses in aged mice (Contreras et al. 2019). We found in our study indeed an association between CMV seropositivity and obesity but unlike a recent meta-analysis (Wang et al. 2017) no increased risk for cardiovascular diseases. Future studies will need to explore the interaction of CMV infection and inflammation in elderly populations in more detail. A study based on the Women’s Health and Aging Studies I and II (Wang et al. 2010) in the USA, which focused on female individuals with a mean age of 74 years, used IgG antibody titer quintiles, and found clear evidence for a reduced survival in the highest (HR 2.79 95% CI 1.22; 6.40) compared to the
first quintile. The effect estimate is considerably higher than the one we obtained for the highest quartile in our study (HR 1.60 95% CI 1.11; 2.23); however, confidence intervals of both studies overlap (Supplementary Figure 1).

We also found a reduced overall survival for individuals seropositive for *H. pylori* with an adjusted HR of 1.36 (95% CI 1.04; 1.79). Contrary to our findings, a study from 2013 based on NHANES III data with 9895 participants did not find an association between *H. pylori* seropositivity and all-cause mortality (HR 1.00, 95% CI 0.84; 1.18) (Chen et al. 2013). Analogous to CMV, the longer exposure time to the infectious agent in the elderly might lead to an accelerated immunosenescence and greater inflammation (De Martinis et al. 2005). Unlike for CMV, our data did not suggest an effect of *H. pylori* IgG antibody titer on mortality.

Individuals seropositive for *B. burgdorferi s.l.* had also a reduced survival time in the multivariable analysis (HR 1.64, 95% CI 1.15; 2.35) of our study. This effect, however, was reduced considerably when we classified seroborderline individuals as seropositive (HR 1.21, 95% CI 0.89; 1.63). To our knowledge, there is no other study, which assessed an association between *B. burgdorferi s.l.* serostatus and all-cause mortality; thus, our study adds new evidence to the literature, which needs to be validated in other population-based cohort studies with long-term follow-up. Unlike for CMV, our data did not suggest an effect of *H. pylori* IgG antibody titer on mortality.

When we combined the investigated antibody titers into a cumulative infection score, we found evidence for a dose-response effect (HR 1.28, 95% CI 1.13; 1.44; per additional score point). Simanek and colleagues built a categorical infection score based on four antibody titers (CMV, HSV-1/2, and *H. pylori*), and found much stronger effect sizes in univariable models than our study did, reaching from an HR of 2.5 when being seropositive for one infection up to an HR of 7.9 when being seropositive for four infections (Simanek et al. 2015). In their adjusted multivariable model, this effect size was more similar to our results, but did no longer show a linear increase with increasing numbers of infections, while our study still does. The linear effect in our study can be explained in the way that every single infection induces a perpetual stimulation of the immune system which then leads to an additive effect (O’Connor et al. 2006). This might correspond to a higher rate of necroptosis, which has been reported in the elderly (Royce et al. 2019), and to an
increased release of damage-associated molecule patterns (DAMPs), which induce inflammation and might lead to a feedback loop. A second potential explanation for the overall increased mortality of those seropositive for several infections is that a high cumulative infection score is a proxy for a failing immune system as present in symptomatic or subclinical immunodeficiency. Immunodeficiencies can be divided into primary immunodeficiencies, the intrinsic malfunctioning of the immune system (Snydman et al. 2014), and secondary immunodeficiencies, which are caused by extrinsic factors like malnutrition or cancer (Chinen and Shearer 2010). Since the

**Table 4** Association between CMV IgG antibody titer quartiles and all-cause mortality (n = 365)

| CMV quartile (linear effect) | Deaths | Follow-up years | Univariable analysis | Multivariable analysis* |
|-----------------------------|--------|----------------|----------------------|------------------------|
|                             |        |                | AFT in % (95%-CI)    | HR (95%-CI)            |
|                             |        |                |                      |                        |
| CMV quartiles               | 250    | 4607           | −9.11 (−15.28; −2.94) | 1.17 (1.05; 1.31)      |
| First (0.0–0.6 AU/ml)**     | 56     | 1335           | 0                    | 1                      |
| Second (0.7–116.7 AU/ml)    | 58     | 1145           | −11.34 (−32.08; 9.40) | 1.22 (0.84; 1.77)      |
| Third (116.8–210 AU/ml)     | 70     | 1037           | −32.07 (−52.03; −12.10) | 1.77 (1.24; 2.51)      |
| Fourth (210.1–250 AU/ml)    | 66     | 1090           | −24.29 (−44.46; −4.12) | 1.54 (1.08; 2.2)       |

*adjusted for age, sex, education years and a comorbidity index;

**first quartile as reference (0–0.6 AU/ml)
defective immune system cannot fulfill its role as a defender, affected individuals are especially susceptible to infectious diseases (Rezaei et al. 2011), so that infections are a major cause for mortality in individuals with an immunodeficiency (Stein et al. 1992). Contrary to the explanation based on the immunosenescence hypothesis, seropositivity for chronic infections would in this case not fulfill the definition of a cause of all-cause mortality, but would rather be a mediator on the causal pathway between immunodeficiency and all-cause mortality.

Seropositivity varied considerably between the different pathogens in our study. While this had an impact on the interpretability of results for highly prevalent pathogens, seropositivity values were generally in line with previous literature (Franck et al. 2017; Korr et al. 2017; Lachmann et al. 2018; Pleyer et al. 2019).

**Limitations**

Our study was based on serum IgG-antibody titers only, but did not have information on the clinical manifestation of the infection, the presence of symptoms or the timing of the exposure to the infectious agent. Therefore, the observed effect is difficult to interpret from a public health perspective. Moreover, our study was not large enough to provide sufficient power to assess the effect of highly prevalent infections like EBV and HSV-1/2; therefore, the results for these viruses are not conclusive. The handling of seroborderline results in the primary analysis might have biased the results. While most analyses were not affected in our sensitivity analysis, the 95% CI for the HR included 1 when counting seroborderline individuals as seropositive in the case of B. burgdorferi s.l. We used education years as a proxy for socioeconomic status although they cover only part of what socioeconomic status means. However, no additional information was available in the underlying cohort study.

**Conclusion**

Our study showed a reduced survival time for individuals seropositive for CMV, H. pylori, and B. burgdorferi s.l. Moreover, we found a linear effect of the number of infections an individual was seropositive for on all-cause mortality. From a public health perspective, vaccination against the causes of chronic infections might extend the overall survival time for the elderly, if seropositivity for chronic infections is indeed causally linked to all-cause mortality. Vaccines against CMV and B. burgdorferi s.l. are already in development (Comstedt et al. 2017; La Rosa et al. 2017), whereas a vaccine against H. pylori seems less likely to be available in the nearer future (Sutton and Boag 2018). Another preventive strategy could be screening and antibiotic treatment for H. pylori colonization (Kim et al. 2015), irrespective of the clinical manifestation. Experimental approaches unspecific to individual pathogens, like mTOR inhibitors, have been shown to prevent senescence in model organisms (Nacarelli et al. 2018) and in first human trials (Chung et al. 2019) and might become a preventive option for the future.

**Acknowledgments** Data assessment for the MEMO Study was conducted within the framework of the Cooperative Health Research in the Augsburg Region (KORA).

**Funding information** Open Access funding provided by Projekt DEAL. The MEMO study was supported by the German Research Society (Deutsche Forschungsgemeinschaft DFG, grant: BE1996/1–1). This analysis was supported by the German Research Society (Deutsche Forschungsgemeinschaft DFG) as part of the German Strategy for Excellence—EXC 2155 “RESIST”—Project ID 39087428. Antibody titers were measured through intramural funds from the Institute of Epidemiology and Social Medicine, University of Muenster, the Institute of Virology, Hannover Medical School and the Helmholtz Centre for Infection Research. KORA was initiated and financed by the Helmholtz Zentrum München—German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research (BMBF) and by the State of Bavaria.

**Compliance with ethical standards**

**Conflicts of interest** The authors declare that they have no conflict of interest.

**Ethics approval** MEMO was approved by the joint ethics committee of the University of Muenster and the Westphalian Chamber of Physicians.

**Statement of informed consent** All individuals provided written informed consent.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence.
Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

Aw D, Silva AB, Palmer DB. Immunosenescence: emerging challenges for an ageing population. Immunology. 2007;120:435–46. https://doi.org/10.1111/j.1365-2567.2007.02555.x.

Bagatkar J, Demuth DR, Scott DA. Tobacco use increases susceptibility to bacterial infection. Tob Indus Dis. 2008;4:12. https://doi.org/10.1186/1617-9625-4-12.

Bartchesky W Jr, et al. Effect of helicobacter pylori infection on IL-8, IL-1-beta and COX-2 expression in patients with chronic gastritis and gastric cancer. Scand J Gastroenterol. 2009;44:53–61. https://doi.org/10.1080/03655520802530853.

Bergstrom T, Vahline A, Alesvig K, Jeansson S, Forsgren M, Lycke E. Primary and recurrent herpes simplex virus type 2-induced meningitis. J Infect Dis. 1990;162:322–30. https://doi.org/10.1093/infdis/162.2.322.

Bransfield RC. Neuropsychiatric Lyme Borreliosis: an overview with a focus on a specialty psychiatrist's clinical practice. Healthcare (Basel, Switzerland). 2018;6:104. https://doi.org/10.3390/healthcare6030104.

Braune BT, Berger K. The influence of depressive mood on activities of daily living and health care utilization in the elderly - the MEMO study on the KORA platform Augsburg. Gesundheitswesen. 2005;67(S1):S176–9.

Casqueiro J, Casqueiro J, Alves C. Infections in patients with HIV infection. J Allergy Clin Immunol. 2010;125:S195–203. https://doi.org/10.1016/j.jaci.2009.08.040.

Chen Y, Segers S, Blaser MJ. Association between Helicobacter pylori and mortality in the NHANES III study. Gut. 2013;62:1262–9. https://doi.org/10.1136/gutjnl-2012-303018.

Chinen J, Shearer WT. Secondary immunodeficiencies, including HIV infection. J Allergy Clin Immunol. 2010;125:S195–203. https://doi.org/10.1016/j.jaci.2009.08.040.

Chung CL, et al. Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial. Geroscience. 2019;41:861–9. https://doi.org/10.1007/s11357-019-00113-y.

Comstedt P, Schütler W, Meinke A, Lundberg U. The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes. PLoS One. 2017;12:e0184357. https://doi.org/10.1371/journal.pone.0184357.

Contreras NA, Sitnik KM, Jefic I, Coplen CP, Čičin-Šain L, Nikolich-Zugich J. Life-long control of cytomegalovirus (CMV) by T resident memory cells in the adipose tissue results in inflammation and hyperglycemia. PLoS Pathog. 2019;15:e1007890. https://doi.org/10.1371/journal.ppat.1007890.

De Martinis M, Franceschi C, Monti D, Ginaldi L. Inflamm-aging and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett. 2005;579:2035–9. https://doi.org/10.1016/j.febslet.2005.02.055.

Diederichs CP, Wellmann J, Bartels DB, Ellert U, Hoffmann W, Berger K. How to weight chronic diseases in multimorbidity indices? Development of a new method on the basis of individual data from five population-based studies. J Clin Epidemiol. 2012;65:679–85. https://doi.org/10.1016/j.jclinepi.2011.11.006.

Dobner J, Kaser S. Body mass index and the risk of infection - from underweight to obesity. Clin Microbiol Infect. 2018;24:24–8. https://doi.org/10.1016/j.cmi.2017.02.013.

Donnelly JP, Lakkur S, Judd SE, Levitan EB, Griffin R, Howard G, et al. Association of Neighborhood Socioeconomic Status With Risk of Infection and Sepsis. Clin Infect Dis. 2018;66:1940–7. https://doi.org/10.1093/cid/cix1109.

Eliassen E, et al. Human Herpesvirus 6 and malignancy: a review. Front Oncol. 2018;8:512. https://doi.org/10.3339/fonc.2018.00512.

Epstein MA, Aichong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet. 1964;1:702–3. https://doi.org/10.1016/s0140-6736(64)91524-7.

Franck C, Hoffmann A, Link A, Schulz C, Wuttig K, Becker E, et al. Prevalence of helicobacter pylori infection among blood donors in Saxony-Anhalt, Germany - a region at intermediate risk for gastric cancer. Z Gastroenterol. 2017;55:653–6. https://doi.org/10.1055/s-0043-16311.

GBD. Global, regional, and national incidence, prevalence, and years lived with disability for 195 diseases and injuries in 198 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789–858. https://doi.org/10.1016/s0140-6736(18 )32279-7.

Gu Z, Zhang C, Wei A, Cui M, Pu J, Lin H, et al. Incidence and risk of respiratory tract infection associated with specific drug therapy in pulmonary arterial hypertension: a systematic review. Sci Rep. 2017;7:16218. https://doi.org/10.1038/s41598-017-16349-7.

Kim SY, Choi DI, Chung J-W. Antibiotic treatment for helicobacter pylori: is the end coming? World J Gastrointest Pharmacol Ther. 2015;6:183–98. https://doi.org/10.4292/wjgpt.v6.i4.183.

Korr G, Thamm M, Czogiel I, Poethko-Mueller C, Bremer V, Jansen K. Decreasing seroprevalence of herpes simplex virus type 1 and type 2 in Germany leaves many people susceptible to genital infection: time to raise awareness and enhance control. BMC Infect Dis. 2017;17:471. https://doi.org/10.1186/s12879-017-2525-1.

La Rosa C, et al. MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults. Blood. 2017;129:114–25. https://doi.org/10.1182/blood-2016-07-729756.

Lachmann R, et al. Cytomegalovirus (CMV) seroprevalence in the adult population of Germany. PLoS One. 2018;13:1–12. https://doi.org/10.1371/journal.pone.0200267.
Lang D, Schott BH, van Ham M, Morton L, Kulikovskaja L, Herrera-Molina R, et al. Chronic toxoplasma infection is associated with distinct alterations in the synaptic protein composition. J Neuroinflammation. 2018;15:216. https://doi.org/10.1186/s12974-018-1242-1.

Mackowiak PA. Microbial latency. Rev Infect Dis. 1984;6:649–68.

Miller CM, Boulter NR, Ikin RJ, Smith NC. The immunobiology of the innate response to Toxoplasma gondii. Int J Parasitol. 2009;39:23–39. https://doi.org/10.1016/j.ijpara.2008.08.002.

Nacarelli T, Azar A, Alhinok O, Orynbayeva Z, Sell C. Rapamycin increases oxidative metabolism and enhances metabolic flexibility in human cardiac fibroblasts. Geroscience. 2018;40:243–56. https://doi.org/10.1007/s11357-018-0030-2.

O’Connor SM, Taylor CE, Hughes JM. Emerging infectious determinants of chronic diseases. Emerg Infect Dis. 2006;12:1051–7. https://doi.org/10.3201/eid1207.060037.

Ogoina D, Onyemelukwe GC. The role of infections in the emergence of non-communicable diseases (NCDs): compelling needs for novel strategies in the developing world. J Infect Public Health. 2009;2:14–29. https://doi.org/10.1016/j.jiph.2009.02.001.

Pawelec G, Gouttefangeas C. T-cell dysregulation caused by chronic antigenic stress: the role of CMV in immunosenescence? Aging Clin Exp Res. 2006;18:171–3.

Piacentini R, et al. HSV-1 and Alzheimer’s disease: more than a hypothesis. Front Pharmacol. 2017;8:345–44. https://doi.org/10.3389/fphar.2016.00097.

Pleyer U, Gross U, Schlüter D, Wilking H, Seeber F. Toxoplasmosis in Germany. Dtsch Arztebl Int. 2019;116:1341.e1322; quiz 1342-1323. https://doi.org/10.3238/arztebl.2019.0435.

Rezaei N, Hedayat M, Aghamohammadi A, Nichols KE. Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies. J Allergy Clin Immunol. 2011;127:1329–1341.e1322; quiz 1342-1323. https://doi.org/10.1016/j.jaci.2011.02.047.

Rolston KVI. Infections in cancer patients with solid tumors: a review. Infect Dis Ther. 2017;6:69–83. https://doi.org/10.1007/s40121-017-0146-1.

Royce GH, Brown-Borg HM, Deepa SS. The potential role of necroptosis in inflamming and aging. Geroscience. 2019;41:795–811. https://doi.org/10.1007/s11357-019-00131-w.

Savva GM, Pachnio A, Kaul B, Morgan K, Huppert FA, Brayne C, et al. Cytomegalovirus infection is associated with increased mortality in the older population. Aging Cell. 2013;12:381–7. https://doi.org/10.1111/ace.12059.

Sharma SA, Tummuru MK, Miller GG, Blaser MJ. Interleukin-8 response of gastric epithelial cell lines to helicobacter pylori stimulation in vitro. Infect Immun. 1995;63:1681–7.

Simanek AM, Dowd JB, Pawelec G, Melzer D, Dutta A, Aiello AE. Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States. PLoS One. 2011;6:e16103. https://doi.org/10.1371/journal.pone.0016103.

Simanek AM, Dowd JB, Zajacova A, Aiello AE. Unpacking the ‘black box’ of total pathogen burden: is number or type of pathogens most predictive of all-cause mortality in the United States? Epidemiol Infect. 2015;143:2624–34. https://doi.org/10.1017/S0950268814003215.

Snyderman DR, et al. Prevention of infections during primary immunodeficiency. Clin Infect Dis. 2014;59:1462–70. https://doi.org/10.1093/cid/ciu646.

Solana R, et al. CMV and immunosenescence: from basics to clinics. Immun Ageing. 2012;11:9. https://doi.org/10.1186/1743-4933-9-23.

Speck SH, Gian d N. Viral latency and its regulation: lessons from the gamma-herpesviruses. Cell Host Microbe. 2010;8:100–15. https://doi.org/10.1016/j.chom.2010.06.014.

Stein M, et al. Causes of death in persons with human immunodeficiency virus infection. Am J Med. 1992;93:387–90. https://doi.org/10.1016/0002-9345(92)90167-a.

Sutton P, Boag JM. Status of vaccine research and development for Helicobacter pylori. Vaccine. 2018. https://doi.org/10.1016/j.vaccine.2018.01.001.

Therneau T. A package for survival analysis in S. version 2.38. 2015.

Truffa AAM, et al. Serious infection after acute myocardial infarction: incidence, clinical features, and outcomes. JACC Cardiovasc Interv. 2012;5:769–76. https://doi.org/10.1016/j.jcin.2012.03.018.

VanderW eele TJ, Shipster I. A new criterion for confounder selection. Biometrics. 2011;67:1406–13. https://doi.org/10.1111/j.1541-0420.2011.01619.x.

Wang GC, Kao WHL, Murakami P, Xue QL, Chiou RB, Detrick B, et al. Cytomegalovirus Infection and the Risk of Mortality and Frailty in Older Women: A Prospective Observational Cohort Study. Am J Epidemiol. 2010;171:1144–52. https://doi.org/10.1093/aje/kwq062.

Wang H, Peng G, Bai J, He B, Huang K, Hu X, et al. Cytomegalovirus infection and relative risk of cardiovascular disease (ischemic heart disease, stroke, and cardiovascular death): a meta-analysis of prospective studies up to 2016. J Am Heart Assoc. 2017:6. https://doi.org/10.1161/jaha.116.005025.

WHO. The World Health Organization MONICA project (monitoring trends and determinants in cardiovascular disease): a major international collaboration. J Clin Epidemiol. 1988;41:105–14.

WHO. WHO Body mass index – BMI. 2019. https://www.who.int/gho/ncd/risk_factors/bmi_text/en/ retrieved: 22.07.2019.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.